Francesca Rafanelli studies colon cancer, specifically looking at a specific cell marker called CD133 that is often associated with cancer stem cells. Her research investigates how the expression of CD133 changes in colon cancer cells when treated with substances like sodium butyrate, which is known to help in cell differentiation. She also examines the characteristics of CD133+ cells, which are found in primary and metastatic colon cancers, as these cells can contribute to the cancer's growth and spread, especially to other organs like the liver.
Key findings
After treating HT29 colon cancer cells with sodium butyrate, CD133 levels dropped from 47% in untreated cells to just 3% after 72 hours, indicating significant changes during cell differentiation.
In her research, CD133+ cells were found to be present in both primary colon tumors and liver metastases, with a higher prevalence in liver metastases.
CD133+ cells were shown to produce larger and more numerous colonies compared to other cancer cell types, suggesting they play a critical role in cancer aggressiveness and the potential spread of the disease.
Frequently asked questions
Does Dr. Rafanelli study colon cancer?
Yes, Dr. Rafanelli's research is focused on colon cancer and the specific behaviors of cancer stem cells.
What treatments has Dr. Rafanelli researched?
Dr. Rafanelli has researched the impact of sodium butyrate on colon cancer cell behavior, particularly its effects on the CD133 marker.
How does Dr. Rafanelli's work relate to patients with metastatic colon cancer?
Her research on CD133+ cells helps identify the most aggressive cancer cells, which can inform treatment strategies for patients with metastatic colon cancer.
What is CD133 and why is it important?
CD133 is a marker found on certain cancer stem cells, and it is important because it helps identify aggressive cancer cells that drive tumor growth and spread.
Can Dr. Rafanelli's findings improve colon cancer detection?
Yes, her work on the expression of CD133 during cell differentiation could lead to better detection methods for colon cancer.
Publications in plain English
The role of liver surgery in simultaneous synchronous colorectal liver metastases and colorectal cancer resections: a literature review of 1730 patients underwent open and minimally invasive surgery.
2022
Minerva surgery
Avella P, Vaschetti R, Cappuccio M, Gambale F, DE Meis L +5 more
Plain English This research looked at the results of surgeries performed on patients with both colorectal cancer and liver metastases at the same time, analyzing data from 1,730 patients. They found that minimally invasive surgery led to shorter hospital stays and fewer complications compared to traditional open surgery. This is important because it shows that less invasive options can improve recovery for patients facing these complex conditions.
Who this helps: This helps patients with colorectal cancer and liver metastases.
Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
2010
Journal of cellular physiology
Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A +5 more
Plain English This study focused on the CD133 molecule, which is thought to be a marker for cancer stem cells in colon cancer. Researchers found that when HT29 colon cancer cells were treated with sodium butyrate, the CD133 levels dropped from about 47% in untreated cells to just 3% after 72 hours. This is important because it suggests that there are complex changes in how CD133 is expressed when colon cells differentiate, which could impact future cancer detection and treatment strategies.
Who this helps: Patients with colon cancer and their doctors.
Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter.
2009
American journal of physiology. Cell physiology
Rettino A, Rafanelli F, Genovese G, Goracci M, Cifarelli RA +2 more
Plain English This study looked at how the Dag1 gene, which is important for cell attachment and muscle development, is controlled in mice. Researchers found specific regions on the DNA that regulate the gene’s activity, particularly a protein called Sp1 that helps turn on the gene, while factors like DNA methylation can turn it off. Understanding these mechanisms could help in finding new treatments for muscle diseases associated with reduced dystroglycan levels.
Who this helps: This benefits patients with muscle disorders and their doctors.
Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer.
2009
European review for medical and pharmacological sciences
Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M +13 more
Plain English This study looked at specific cancer cells called CD133+ cells in colon cancer and its spread to the liver. Researchers found that these CD133+ cells existed in both colon tumors and liver metastases, with a higher percentage in liver metastases. The CD133+ cells were also shown to produce larger and more numerous colonies compared to other cancer cells, indicating they may be key drivers of cancer growth and spread.
Who this helps: This research benefits patients with colon cancer by providing insight into the most aggressive cancer cells.
Influence of Ggamma-158C --> and beta- (AT)x(T)y globin gene polymorphisms on HbF levels in Italian beta-thalassemia carriers and wild-type subjects.
2006
Haematologica
Guida V, Cappabianca MP, Colosimo A, Rafanelli F, Amato A +1 more
Plain English This study looked at how certain genetic variations affect levels of fetal hemoglobin (HbF) in Italian individuals with beta-thalassemia and those without it. Researchers found that two specific genetic changes, -158GgammaT and (AT)9(T)5, were linked to higher HbF levels in beta-thalassemia carriers, while these changes did not affect individuals without the condition. This matters because higher HbF levels can lead to milder symptoms in beta-thalassemia patients, improving their health outcomes.
Who this helps: This benefits patients with beta-thalassemia.